Advisory Board

Christian Klein, Head of Oncology Programmes, Roche Pharmaceutical Research and Early Development Christian Klein
Head of Oncology Programmes
Roche Pharmaceutical Research and Early Development

Hans-Peter Gerber, CSO and President, Maverick Therapeutics Hans-Peter Gerber
CSO and President
Maverick Therapeutics

Ahuva Nissim, Reader, Antibody and Therapeutic Engineering, Queen Mary University of London Ahuva Nissim
Reader, Antibody and Therapeutic Engineering
Queen Mary University of London

Alain Beck, Senior Director, NBEs Analytical Chemistry, Pierre Fabre, Associate Editor, mAbs Alain Beck
Senior Director, NBEs Analytical Chemistry, Pierre Fabre ; Associate Editor, mAbs

Ulrich Brinkmann, Scientific Director, Roche Pharma Research & Early Development, Roche Innovation Centre Munich Ulrich Brinkmann
Scientific Director, Roche Pharma Research & Early Development
Roche Innovation Centre Munich

Ezio Bonvini, SVP & CSO, Research, Macrogenics Ezio Bonvini
SVP & CSO, Research
Macrogenics 

John Delaney, Executive Director, Amgen Biologics Discovery John Delaney
Executive Director
Amgen Biologics Discovery 

Christian Rommel, Global Head of Oncology Discovery, Roche Christian Rommel
Global Head of Oncology Discovery
Roche

Janice Reichert, Executive Director, The Antibody Society; Editor-in-Chief, mABs Janice Reichert
Executive Director, The Antibody Society ; Editor-in-Chief, mABs

Michael DeRidder, Senior Director, Early Pipeline Commercial Strategy for Oncology Cell Therapy, Neuroscience, and ADD, GSK Michael DeRidder
Senior Director, Early Pipeline Commercial Strategy for Oncology Cell Therapy, Neuroscience, and ADD
GSK

Peter Senter, VP, Distinguished Research Fellow, Seattle Genetics Peter Senter
VP, Distinguished Research Fellow
Seattle Genetics

 

JOIN THE ADVISORY BOARD

 

Co-located with 

Part of


European Antibody Congress 29-31 October, Basel, Switzerland

Part of the  Festival of Biologics

Sign Up for Event Updates